OpenBind releases first open dataset and AI model for drug discovery
13 May 2026
The OpenBind consortium’s first release of experimental data marks a milestone in efforts to improve how artificial intelligence (AI) is used in drug discovery.
MSc in Global Healthcare Leadership students launch global health venture platform, Synergya, a new platform for scaling health and sustainability ventures
11 May 2026
Two students from the University of Oxford’s MSc in Global Healthcare Leadership programme, jointly delivered by the Nuffield Department of Primary Care Health Sciences (NDPCHS) and Saïd Business School, have co-founded a new social enterprise called ‘Synergya’, designed to help health and sustainability ventures scale through structured collaboration.
University of Oxford and Serum Institute of India agree licence to advance the next-generation multi-stage malaria vaccine candidate component
25 April 2026
The University of Oxford, through Oxford University Innovation (OUI), and the Serum Institute of India (SII), a Cyrus Poonawalla group company and the world’s largest vaccine manufacturer by volume, have entered into a licence agreement to support the development and manufacture of the new malaria vaccine candidate R78C, based on two Plasmodium falciparum blood-stage antigens (RIPR and CyPRA), for use in clinical settings.
Oxford-ZEISS Centre of Excellence in Biomedical Imaging to develop next-generation imaging technology for drug-profiling in live cells
14 April 2026
The pioneering technology will be able to precisely quantify drug behaviour at the cellular level for the development of novel therapeutics.
Hepatology at Home: patient-centred liver care beyond the hospital
31 March 2026
Liver disease is a growing and urgent challenge for the NHS. Unplanned admissions have risen sharply in the past decade (more than 50%), and around 35% of patients die within 60 days of discharge. Many patients experience frequent, unpredictable complications.
Oxford University spinout Dark Blue Therapeutics acquired to advance leukaemia treatment
20 March 2026
Oxford University spinout Dark Blue Therapeutics has been acquired by global biotechnology company Amgen in a deal worth up to US$840 million, marking a major milestone for Oxford-led cancer research and innovation. The deal reflects years of collaborative, multidisciplinary work across the University and its partners to translate fundamental research into promising new medicines.
GSK, University of Oxford and Imperial College London launch centre to create computer models of lungs, liver, kidneys and cartilage
19 March 2026
A new research centre backed with £11 million from GSK will build open-source digital twins of organs for in-silico research to advance disease understanding and speed up development of new drugs.
Oxford and Serum Institute of India sign IP license agreement to advance NipahB vaccine candidate
13 March 2026
The University of Oxford and Serum Institute of India Pvt. Ltd. (SII), a Cyrus Poonawalla Group company and the world’s largest vaccine manufacturer, have signed an Intellectual Property license agreement to advance the development and manufacture of the ChAdOx1 NipahB vaccine candidate.
Guest Lecture series: Highlighting breakthroughs in women’s health and stillbirth prevention
23 February 2026
The latest event of the Guest Lecture series welcomed Professor Sarah Stock, Programme Director of In Utero at Wellcome Leap, who delivered a compelling talk titled Breakthroughs in Women’s Health.
New Oxford-led initiative launches to train future leaders in transformative technologies for pharmaceutical research
5 February 2026
GSK, in partnership with the Universities of Oxford, Cambridge and Southampton, has launched Transformative Technologies in Pharmaceutical Sciences (TTPS). This cross-sector doctoral training programme will equip a new generation of researchers to translate basic scientific research and biological understanding into novel technologies, vaccines, therapies and drugs that will accelerate patient benefit. The new programme is a part of the Industrial Landscape Award programme announced by BBSRC.
Oxford spinout launches AI-based ultrasound technology to improve early detection of pregnancy complications
2 February 2026
A new University of Oxford spinout, Oxailis Ltd, has launched an AI-based ultrasound technology that enables healthcare professionals to measure perfusion (how effectively oxygen-rich blood is delivered to tissue), using existing standard ultrasound hardware and without the need for contrast agents.
NDORMS and NDCN collaborate with Oxford University Hospitals to form the Kadoorie Institute for Trauma, Emergency and Critical Care
23 January 2026
Oxford Trauma and Emergency Care at Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences (NDORMS), along with the Critical Care Research Team at Nuffield Department of Clinical Neurosciences (NDCN) have formally become a new Institute within the University of Oxford: the Kadoorie Institute for Trauma, Emergency and Critical Care.
Oxford researchers join Novo, Gates, and Wellcome to tackle antimicrobial resistance
22 January 2026
Oxford researchers from the Nuffield Department of Medicine are part of a major new international initiative with the Novo Nordisk Foundation, Wellcome and the Gates Foundation to accelerate the discovery of urgently needed antibiotics. The Gram-Negative Antibiotic Discovery Innovator (Gr-ADI) brings together global expertise to tackle drug-resistant Gram-negative infections, one of the most serious threats to global health.
Oxford cancer researchers welcome UK AI for Science Strategy, highlighting the opportunity for national AI-ready cancer data
11 December 2025
Oxford researchers have welcomed the UK government’s new AI for Science Strategy, which sets out an ambitious plan to harness artificial intelligence, sovereign supercomputing and high-quality scientific data to accelerate discovery in the life sciences.
Oxford and GSK launch Experimental Medicine Collaboration
18 November 2025
GSK invests £10 million over five years to establish the Experimental Medicine Collaboration with the University of Oxford.
Terumo completes acquisition of University of Oxford spinout OrganOx for a record $1.5bn
31 October 2025
OrganOx, a pioneering Oxford University spinout transforming kidney and liver transplantation, has been fully acquired by Terumo Corporation, a global medical technology company headquartered in Tokyo, Japan, for US$1.5 billion, marking the largest exit in Oxford University’s spinout portfolio to date and the first in excess of £1bn. The agreement for the acquisition was announced in August 2025.
Innovative Oxford child anxiety treatment to be rolled out internationally
21 October 2025
An effective online treatment for childhood anxiety developed by a team at the University of Oxford is to be adapted and tested in five countries in Asia and South America, with the aim of driving widespread implementation in the future.
Oxford’s OrganOx is shortlisted for the MacRobert Award 2025
17 June 2025
The Royal Academy of Engineering has announced the finalists for the 2025 MacRobert Award, the longest running and most prestigious prize for UK engineering innovation.
New therapies developed by Oxford experts offer online support for anxiety and post-traumatic stress disorders
23 September 2024
Four internet-based therapies developed by experts at the University of Oxford’s Department of Experimental Psychology and Department of Psychiatry are proving helpful for patients with social anxiety disorder and post-traumatic stress disorders and for children with anxiety disorders.
Oxford part of new international Pioneer Centre for medical data research
20 August 2024
The University of Oxford has joined forces with Aarhus University and the University of Copenhagen to create a new Pioneer Centre that will become a significant international partner for data-driven medical research. The Pioneer Centre is anchored at Aarhus University with hub sites at each of the three universities and with a total grant of DKK 250 million.